We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Multi-Omics Tool Illuminates Cancer Progression

By LabMedica International staff writers
Posted on 22 Oct 2025

Tracking how cancers evolve into more aggressive and therapy-resistant forms has long been a challenge for researchers. More...

Many current tools can only capture limited genetic information from tumor samples, especially when the samples are preserved rather than fresh. A new technology now allows scientists to record multiple gene mutations while simultaneously tracking gene activity in single cancer cells, enabling unprecedented insights into how cancers progress and resist treatment.

Developed by Weill Cornell Medicine (New York, NY, USA) in collaboration with the University of Adelaide (Adelaide, Australia), the new tool, called GoT-Multi, is an advanced version of the earlier GoT (Genotyping of Transcriptomes) platform. While GoT was innovative, it was limited in the number and types of mutations it could detect and could only work on fresh or frozen samples. GoT-Multi overcomes these barriers, handling preserved samples embedded in wax, a widely available resource in hospital pathology labs worldwide.

GoT-Multi is a “single-cell multi-omics” tool that integrates multiple layers of data from thousands of individual cancer cells. It can process large sample sets rapidly and link cellular gene activity with genetic mutations, revealing how specific mutations drive different cancer cell behaviors such as growth and inflammation. This expanded functionality allows researchers to map disease progression with unprecedented clarity.

In a key demonstration, the team applied GoT-Multi to tissue samples from patients whose chronic lymphocytic leukemia had progressed into aggressive large B-cell lymphoma, a process known as Richter Transformation. According to findings published in Cell Genomics, the tool analyzed more than 45,000 tumor cells, identifying over two dozen mutations and correlating them with distinct cellular activities, providing new insight into how malignancy develops.

Researchers are now using GoT-Multi to study therapy-resistant lymphomas and to map other cancers and precancerous stages. By linking genetic and functional data at single-cell resolution, the tool can uncover key pathways of resistance and evolution, potentially pointing to new therapeutic targets. The team anticipates that this platform will guide the development of precision treatments and deepen understanding of tumor biology.

“This technology gives us substantial new power to answer important questions about how cancers evolve, from the beginnings of pre-cancerous neoplastic outgrowths to transformation into malignancy and finally to therapy resistance,” said study co-senior author Dr. Anna S. Nam.

Related Links:
Weill Cornell Medicine
University of Adelaide


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.